CJC-1295 no DAC 5mg / IPA 5mg

This blend combines two well-researched growth hormone-stimulating peptides with complementary mechanisms of action. CJC-1295 no DAC is a synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. Ipamorelin is a synthetic five-amino acid Growth Hormone Secretagogue (GHS) that works via ghrelin receptor binding to independently stimulate GH release. When combined, the two peptides engage different receptor pathways simultaneously — GHRH receptors and GHS receptors — potentially producing a synergistic amplification of growth hormone secretion greater than either peptide achieves alone.

Chemical Makeup

CJC-1295 no DAC: C152H252N44O42 | 3367.9 g/mol | Also known as: Modified GRF 1-29, Mod GRF 1-29

Ipamorelin: C38H49N9O5 | 711.86 g/mol | Also known as: NNC 26-0161

Research Highlights

• Growth Hormone Release — CJC-1295 no DAC has been shown to stimulate pulsatile GH release in a pattern closely mimicking natural secretion, while Ipamorelin research suggests it may produce significant GH elevation — with one study observing up to a 60-fold increase over baseline — without significantly affecting other pituitary hormones such as prolactin or ACTH.
• Synergistic GH Secretion — Research indicates that combining a GHRH analog with a GHS receptor agonist may produce amplified GH release compared to either compound alone, as the two pathways appear to work cooperatively at the pituitary level.
• Muscle & Bone Anabolism — Elevated GH and downstream IGF-1 production stimulated by both peptides may support cellular proliferation, muscle anabolism, and bone mineral content — consistent with independent research findings on each compound.
• Lipolysis — Increased GH levels facilitated by this combination may promote lipolysis and fat oxidation, particularly at visceral and abdominal adipose depots, consistent with known GH-mediated fat metabolism research.
• Recovery & Tissue Repair — GH and IGF-1 elevation associated with both peptides has been studied in the context of accelerated tissue repair, collagen synthesis, and cellular regeneration across multiple research models.
• Selectivity & Tolerability — Ipamorelin's high selectivity for GH release without significantly impacting cortisol or prolactin, combined with CJC-1295 no DAC's short half-life and pulsatile release profile, makes this a widely researched combination for studies requiring controlled GH stimulation.

Available for research and laboratory purposes only.